Skip to main navigation
Sana Biotechnology, Inc Logo

    Investor Relations

  • Home
  • News Releases
  • Events and Presentations
  • Corporate Governance
    Documents & Charters Our Team Committee Composition
  • Stock
    Stock Quote & Chart Historic Price Lookup
  • Financial Information
    SEC Filings
  • Resources
    Email Alerts Contact IR

News Releases

Feb 02, 2023
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
SEATTLE, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Guggenheim Healthcare Talks 5 th Annual Oncology Conference at 1:00 p.m.
Jan 26, 2023
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
Goal is to report initial SC291 clinical data this year Goal is to submit a second IND from the platform this year for SC262, a hypoimmune-modified CD22-targeted allogeneic CAR T therapy SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc.
Jan 03, 2023
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 41 st Annual J.P. Morgan Healthcare Conference at 3:45 p.m.

Shareholder Tools

  • Print Page
  • Email Alerts
  • RSS
  • © 2020-2023 Sana Biotechnology, Inc. All rights reserved.

Footer Bottom

  • Privacy Policy |
  • Terms of Use